Nitric oxide synthase genes and their interactions with environmental factors in Parkinson’s disease
暂无分享,去创建一个
Dana B. Hancock | William K. Scott | Eden R. Martin | Jeffery M. Vance | W. Scott | E. Martin | J. Vance | D. Hancock | W. Scott
[1] Yi-Ju Li,et al. Methods for interaction analyses using family‐based case‐control data: conditional logistic regression versus generalized estimating equations , 2007, Genetic epidemiology.
[2] Y. Agid,et al. Nitric oxide synthase and neuronal vulnerability in parkinson's disease , 1996, Neuroscience.
[3] Gudmundur A. Thorisson,et al. The International HapMap Project Web site. , 2005, Genome research.
[4] Eden R Martin,et al. No gene is an island: the flip-flop phenomenon. , 2007, American journal of human genetics.
[5] Ted M. Dawson,et al. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease , 1999, Nature Medicine.
[6] Mark Daly,et al. Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..
[7] E R Martin,et al. Genotype‐based association test for general pedigrees: The genotype‐PDT , 2003, Genetic epidemiology.
[8] Jason H. Moore,et al. An application of conditional logistic regression and multifactor dimensionality reduction for detecting gene-gene Interactions on risk of myocardial infarction: The importance of model validation , 2004, BMC Bioinformatics.
[9] Eden R Martin,et al. Pesticide exposure and risk of Parkinson's disease: A family-based case-control study , 2008, BMC neurology.
[10] G. Bing,et al. Up-regulation of inducible nitric oxide synthase in the substantia nigra by lipopolysaccharide causes microglial activation and neurodegeneration , 2003, Neurobiology of Disease.
[11] J. Dichgans,et al. Deficiency of Inducible Nitric Oxide Synthase Protects Against MPTP Toxicity In Vivo , 2000, Journal of neurochemistry.
[12] Mahlon R DeLong,et al. Prevalence, etiology, and treatment of depression in Parkinson’s disease , 2003, Biological Psychiatry.
[13] W. Willett,et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. , 2003, Archives of neurology.
[14] E R Martin,et al. Letter to the Editor Correcting for a Potential Bias in the Pedigree Disequilibrium Test , 2022 .
[15] W. Scott,et al. Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson disease. , 2007, Archives of neurology.
[16] M. Ebadi,et al. Peroxynitrite and mitochondrial dysfunction in the pathogenesis of Parkinson's disease. , 2003, Antioxidants & redox signaling.
[17] J. H. Moore,et al. A novel method to identify gene–gene effects in nuclear families: the MDR‐PDT , 2006, Genetic epidemiology.
[18] J. Stamler,et al. A mechanism of paraquat toxicity involving nitric oxide synthase. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[19] T. Foroud,et al. Reliability of reported age at onset for Parkinson's disease , 2003, Movement disorders : official journal of the Movement Disorder Society.
[20] E R Martin,et al. Identification of significant association and gene-gene interaction of GABA receptor subunit genes in autism. , 2005, American journal of human genetics.
[21] B S Weir,et al. A comparative study of sibship tests of linkage and/or association. , 1998, American journal of human genetics.
[22] F. Coppedè,et al. Genes and the Environment in Neurodegeneration , 2006, Bioscience reports.
[23] Miguel A Hernán,et al. A meta‐analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease , 2002, Annals of neurology.
[24] Y. Shugart,et al. An evaluation of power and type I error of single-nucleotide polymorphism transmission/disequilibrium-based statistical methods under different family structures, missing parental data, and population stratification. , 2007, American journal of human genetics.
[25] Eden R Martin,et al. Accounting for linkage in family-based tests of association with missing parental genotypes. , 2003, American journal of human genetics.
[26] A. Lees,et al. Ageing and Parkinson's disease: substantia nigra regional selectivity. , 1991, Brain : a journal of neurology.
[27] J. H. Moore,et al. Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. , 2001, American journal of human genetics.
[28] S. Gabriel,et al. Efficiency and power in genetic association studies , 2005, Nature Genetics.
[29] P. Amouyel,et al. Association between Parkinson's disease and polymorphisms in the nNOS and iNOS genes in a community-based case-control study. , 2003, Human molecular genetics.
[30] D. Berg,et al. Comprehensive association analysis of the NOS2A gene with Parkinson disease , 2006, Neurology.
[31] J. Witte,et al. Asymptotic bias and efficiency in case-control studies of candidate genes and gene-environment interactions: basic family designs. , 1999, American journal of epidemiology.
[32] P. Silburn,et al. Parkinson's disease and family history. , 2006, Parkinsonism & related disorders.
[33] T. Dawson,et al. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[34] S. Khuder,et al. Environmental risk factors and Parkinson's disease: a metaanalysis. , 2001, Environmental research.
[35] Eric Jacobs,et al. Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease , 2005, Annals of neurology.
[36] Hermona Soreq,et al. Gene–environment interactions in sporadic Parkinson's disease , 2006, Journal of neurochemistry.
[37] Werner J. Schmidt,et al. Chronic administration of rotenone increases levels of nitric oxide and lipid peroxidation products in rat brain , 2004, Experimental Neurology.
[38] K. Soliman,et al. Inhibitory effects of cigarette smoke on glial inducible nitric oxide synthase and lack of protective properties against oxidative neurotoxins in vitro. , 2005, Neurotoxicology.
[39] Yi-Ju Li,et al. NOS2A and the modulating effect of cigarette smoking in Parkinson's disease , 2006, Annals of neurology.
[40] M. Colasanti,et al. The dual personality of NO. , 2000, Trends in pharmacological sciences.
[41] N. Wood,et al. Understanding the molecular causes of Parkinson's disease. , 2006, Trends in molecular medicine.
[42] V. Álvarez,et al. No association between Parkinson's disease and three polymorphisms in the eNOS, nNOS, and iNOS genes , 2007, Neuroscience Letters.
[43] M. Colasanti,et al. Cross-talk between constitutive and inducible NO synthase: an update. , 2006, Antioxidants & redox signaling.
[44] E. Martin,et al. A test for linkage and association in general pedigrees: the pedigree disequilibrium test. , 2000, American journal of human genetics.
[45] A. Singleton,et al. Confirmation of the protective effect of iNOS in an independent cohort of Parkinson disease , 2004, Neurology.